5 More Countries Approve Pfizer Arthritis Drug Xeljanz

Law360, New York (July 15, 2013, 6:03 PM EDT) -- Pfizer Inc.'s rheumatoid arthritis drug Xeljanz has received approval for use in five more countries, including Switzerland, the company said Monday, adding that it hoped a European Union health board would soon reverse a negative review of the drug.

Pfizer said the 5-milligram version of its twice-a-day pill for adults with moderate-to-severe rheumatoid arthritis has been approved in Argentina, Kuwait and the United Arab Emirates, while the 5- and 10-milligram versions have been approved in Russia and Switzerland. Switzerland is the first European country to approve the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.